Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States

Vikas Kumar Dawra¹, Kathleen Pelletier², Kyle Matschke³, Haihong Shi², Anne Hickman², Susan Zhou⁴, Rajesh Krishna⁴,⁵, and Vaishali Sahasrabudhe²

Abstract
A fixed-dose combination (FDC) product of a selective sodium-glucose cotransporter 2 inhibitor ertugliflozin and immediate-release metformin is approved for type 2 diabetes mellitus in the United States, European Union countries, Canada, and other countries. Two studies were conducted to assess the bioequivalence of metformin in the ertugliflozin/metformin FDC tablets to the corresponding doses of Canadian-sourced metformin (Glucophage) coadministered with ertugliflozin. Both studies were phase 1 randomized, open-label, 2-period, single-dose crossover studies (n = 32) in which healthy subjects received an ertugliflozin/metformin FDC tablet (2.5/500 mg or 7.5/850 mg) and the respective doses of the individual components (ertugliflozin coadministered with Canadian-sourced metformin) under fasted (n = 18) or fed (n = 14) conditions. Blood samples were collected 72 hours postdose to determine metformin concentrations. The 90% confidence intervals were within the bioequivalence acceptance criteria for the adjusted geometric mean ratios (FDC:coadministered) for metformin area under the plasma concentration-time curve from time zero to time t, where t is the last point with a measurable concentration and peak observed plasma concentration for both dose strengths under fasted and fed conditions. All study medications were well tolerated. Bioequivalence was demonstrated for the metformin component of the ertugliflozin/metformin FDC tablets and the corresponding doses of the Canadian-sourced metformin coadministered with ertugliflozin.

Keywords
bioequivalence, diabetes, fixed-dose combination, metformin, sodium-glucose cotransporter 2 inhibitor

Ertugliflozin is an oral selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) that acts by preventing renal glucose reabsorption, resulting in urinary glucose excretion and thereby reducing plasma glucose and glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes (T2DM).¹⁻⁴ Ertugliflozin is approved in the United States, European Union countries, Canada, and other countries. Phase 3 studies have demonstrated that ertugliflozin—administered either as monotherapy or added to metformin alone or in addition to sitagliptin—provides clinically meaningful glycemic control and reduction in systolic blood pressure and body weight.⁵⁻¹⁴

A single oral dose of ertugliflozin is absorbed with a time to maximum plasma concentration (Tmax) of 1 hour (fasted) to 2 hours (fed) and a terminal half-life (t1/2)
Ertugliflozin demonstrates ~100% absolute bioavailability and a dose-proportional increase in exposure within the tested dose range of 0.5-300 mg\textsuperscript{1}; the pharmacokinetics (PK) of ertugliflozin are comparable in healthy people and patients with T2DM.\textsuperscript{16} Ertugliflozin is categorized as a Biopharmaceutics Classification System (BCS) class I compound based on high solubility and high permeability characteristics.\textsuperscript{17,18} Food has no clinically meaningful effect on ertugliflozin PK, and, therefore, it can be taken without regard to meals.\textsuperscript{15} Ertugliflozin also exhibited time-independent PK, and steady-state concentrations were achieved by 4 to 6 days after initiation of once-daily dosing, consistent with its half-life.\textsuperscript{19} Ertugliflozin is primarily metabolized via the glucuronidation pathway (86%) to 2 principal pharmacologically inactive glucuronide metabolites, M5a and M5c, which account for ~37% of the dose recovered in urine; oxidation plays a minor role (12%) in the metabolism of ertugliflozin.\textsuperscript{20} There is negligible renal excretion of ertugliflozin (~1.5% of the oral dose),\textsuperscript{20} and no clinically meaningful effect on ertugliflozin PK was observed in patients with renal impairment\textsuperscript{16} or in patients with mild or moderate hepatic impairment.\textsuperscript{21} Drug interaction studies assessing ertugliflozin being coadministered with sitagliptin, metformin, glimepiride, or simvastatin did not show any clinically relevant interactions, and, therefore, these drugs can be safely coadministered with ertugliflozin without the need for dose adjustment.\textsuperscript{19}

Metformin is the most commonly used first-line treatment for patients with T2DM.\textsuperscript{22} Metformin, a biguanide, improves glycemic control by lowering hepatic glucose production as well as glucose absorption and improving insulin-mediated glucose uptake and utilization.\textsuperscript{23} Metformin uptake in the liver is mostly mediated by organic cation transporter (OCT) 1 and possibly OCT3.\textsuperscript{24} Metformin is excreted by human ortholog multidrug and toxin extrusion (MATE) transporters (MATE1 and MATE2-K).\textsuperscript{24} Under fasting conditions, the bioavailability of metformin is ~50% to 60%.\textsuperscript{25} It is not highly bound to protein,\textsuperscript{26} and following oral administration, the renal system eliminates 90% of the absorbed drug within the first 24 hours, with an elimination half-life of 6.2 hours in plasma and ~17.6 hours in blood.\textsuperscript{27}

Combined administration of ertugliflozin and metformin, with their different and complementary mechanisms of action, can provide incremental improvement in glycemic control in patients with T2DM compared with either agent alone.\textsuperscript{7} Fixed-dose combinations (FDCs) of ertugliflozin and immediate-release metformin are in use in the United States, European Union countries, Canada, and other countries. Six ertugliflozin/metformin FDC strengths were developed, with tablets containing ertugliflozin/metformin 2.5/500, 2.5/850, 2.5/1000, 7.5/500, 7.5/850, and 7.5/1000 mg. Immediate-release metformin should be given in divided doses and is typically dosed twice daily; therefore, ertugliflozin/metformin FDC containing immediate-release form of metformin is dosed twice daily as well. Consequently, 2.5 and 7.5 mg twice-daily doses of ertugliflozin, which is half the approved once-daily doses, were used for the FDC formulation. To bridge phase 3 efficacy and safety data of ertugliflozin and metformin\textsuperscript{7} with the FDC tablet formulation, 4
Table 1. Demographic Characteristics

| Characteristic | Metformin 500 mg With Ertugliflozin 2.5 mg | Metformin 850 mg With Ertugliflozin 7.5 mg |
|----------------|------------------------------------------|------------------------------------------|
|                | Fasted (n = 18) | Fed (n = 14) | Total (N = 32) | Fasted (n = 18) | Fed (n = 14) | Total (N = 32) |
| Sex, n         |               |             |               |               |             |               |
| Male           | 8             | 7           | 15            | 11            | 5           | 16            |
| Female         | 10            | 7           | 17            | 7             | 9           | 16            |
| Age, years     |               |             |               |               |             |               |
| Mean (SD)      | 34.5 (7.2)    | 33.3 (8.2)  | 34.0 (7.6)    | 35.8 (8.0)    | 34.2 (8.1)  | 35.1 (7.9)    |
| Range          | 24-47         | 20-47       | 20-47         | 23-53         | 25-51       | 23-53         |
| Race, n        |               |             |               |               |             |               |
| White          | 4             | 0           | 4             | 3             | 1           | 4             |
| Black          | 8             | 11          | 19            | 11            | 11          | 22            |
| Other          | 6             | 3           | 9             | 4             | 2           | 6             |
| Weight, kg     |               |             |               |               |             |               |
| Mean (SD)      | 69.5 (11.6)   | 73.9 (13.8) | 71.4 (12.6)   | 77.7 (13.3)   | 72.8 (11.4) | 75.5 (12.6)   |
| Range          | 50.7-90.1     | 50.6-94.8   | 50.6-94.8     | 57.3-99.9     | 54.9-89.6   | 54.9-99.9     |
| BMI, kg/m²     |               |             |               |               |             |               |
| Mean (SD)      | 21.4 (3.1)    | 26.2 (2.8)  | 25.6 (3.0)    | 26.7 (2.9)    | 25.1 (2.9)  | 26.0 (3.0)    |
| Range          | 19.4-29.3     | 21.1-29.6   | 19.4-29.6     | 21.0-30.0     | 20.0-28.9   | 20.0-30.0     |

BMI, body mass index; N, number of subjects in the study; n, number of subjects in a cohort; SD, standard deviation.

crossover phase 1 single-dose studies that were randomized and open-label with 2 periods and 2 sequences were conducted in healthy participants in the fasted state and demonstrated the bioequivalence of ertugliflozin and metformin in the ertugliflozin/metformin FDC tablets at doses of 2.5/500, 7.5/850, or 7.5/1000 mg to the corresponding doses of the individual components (United States- or European Union-sourced metformin [Glucophage]) when coadministered with ertugliflozin.28

Here we report 2 additional phase 1 randomized, open-label, 2-period, 2-sequence, single-dose crossover studies in healthy participants to assess the bioequivalence of the metformin component in the ertugliflozin/metformin FDC tablets at doses of 2.5/500 or 7.5/850 mg compared with the respective doses of Canadian-sourced metformin (Glucophage)—hereafter, referred to as metformin coadministered with ertugliflozin.28

Methods

Study Conduct

Two phase 1 randomized, open-label, 2-period, 2-sequence, single-dose crossover studies were conducted in healthy participants (32 subjects enrolled in each study). Both studies were conducted in compliance with the ethical principles of the Declaration of Helsinki and in compliance with all International Conference on Harmonisation Good Clinical Practice guidelines. Signed and dated informed consent was obtained from all subjects. The studies were conducted at the Pfizer Clinical Research Unit in New Haven, Connecticut. The final protocol and informed consent document were reviewed and approved by IntegReview Ethical Review Board, Austin, Texas.

Study Design and Treatment

During each study subjects underwent 1 screening visit and 2 study treatment periods. Screening took place in
Figure 2. Mean (standard deviation [SD]) plasma metformin concentration-time profiles in linear (principal plot) with semilogarithmic (inset plot) scales following single oral dose of ertugliflozin coadministered with Canadian-sourced metformin (Glucophage) or as a fixed-dose combination (FDC) under fasted or fed conditions. Note: Samples below the lower limit of quantification were set to 0 in the calculation of summary statistics and for pharmacokinetic analysis.

period 1 within 28 days of the first dose of the study medication. All the study participants were admitted to the clinical research unit on day 0 of each period prior to dosing. A single dose of the ertugliflozin/metformin FDC tablet (2.5/500 or 7.5/850 mg) or the respective doses of the individual components (ertugliflozin 2.5 or 7.5 mg coadministered with metformin 500 or 850 mg, respectively) were administered according to 1 of 2 sequences in a crossover design, under fasted or fed conditions as required under Health Canada guidance (Figure 1). A washout period of ≥ 7 days separated dosing between consecutive crossover periods. A single tablet of the ertugliflozin/metformin FDC was administered. Similarly, a single tablet of metformin 500- and 850-mg doses and the ertugliflozin 2.5-mg dose were coadministered, whereas the ertugliflozin 7.5-mg dose was administered as one 5-mg and one 2.5-mg tablet.

Fasted subjects (n = 18) received study medication after a minimum 10-hour fast, and food was not allowed for 4 hours postdose. Fed subjects (n = 14) received a standard high-fat, high-calorie breakfast after a minimum 10-hour fast. Participants received study medication ~30 minutes after the start of the breakfast, which was consumed within 25 minutes. Additional food was not permitted for at least 4 hours postdose. All participants were requested to not lie down or drink liquid other than water for the first 4 hours postdose. Water was also not allowed 1 hour predose and 1 hour after administering study medication (except for the liquid consumed with the medica-
**Table 2. Descriptive Summary of Plasma Metformin PK Parameter Values Under Fasted or Fed Conditions**

| Parameter                  | Fasted                                      | Fed                                           |
|----------------------------|---------------------------------------------|-----------------------------------------------|
|                            | Metformin 500 mg With Ertugliflozin 2.5 mg  | Metformin 500 mg With Ertugliflozin 2.5 mg   |
|                            | FDC Coadministered                          | FDC Coadministered                           |
| N, n                       | 18, 14                                      | 14, 8                                        |
| AUC_{inf}                  | $6945 \pm 2715.16$                         | $7198 \pm 2197.6$                           |
|                             | $6904 (31)$                                 | $7202 (29)$                                  |
| AUC_{last}                 | $6653 \pm 2222.0$                          | $5259 (24)$                                  |
|                            | $6316 (34)$                                 | $5388 \pm 1422.5$                           |
| C_{max}                    | $1096 (30)$                                 | $641.7 (20)$                                 |
|                            | $1144 \pm 364.33$                          | $652.6 \pm 121.27$                           |
| T_{max}                    | $2.00 (1.00-3.02)$                          | $6.00 \pm 4.07$                              |
| t_{1/2}                    | $14.21 \pm 13.71$                          | $15.44 \pm 11.69$                           |

| Parameter                  | Fasted                                      | Fed                                           |
|                            | Metformin 850 mg With Ertugliflozin 7.5 mg  | Metformin 850 mg With Ertugliflozin 7.5 mg   |
|                            | FDC Coadministered                          | FDC Coadministered                           |
| N, n                       | 18, 15                                      | 14, 9                                        |
| AUC_{inf}                  | $9477 (26)$                                 | $8235 (27)$                                  |
|                             | $9669 (35)$                                 | $8802 (27)$                                  |
| AUC_{last}                 | $9446 (18)$                                 | $8570 \pm 248.82$                           |
|                            | $9590 \pm 173.18$                          | $9073 \pm 2371.0$                           |
| C_{max}                    | $1453 (28)$                                 | $8525 \pm 1797.9$                           |
|                            | $1455 \pm 244.93$                          | $8096 \pm 1875.0$                           |
| T_{max}                    | $2.00 (1.00-3.02)$                          | $3.53 (1.03-4.10)$                           |
| t_{1/2}                    | $16.69 \pm 11.55$                          | $16.05 \pm 11.59$                           |

PK parameter units are as follows: AUC_{inf}, area under plasma concentration-time profile from time 0 extrapolated to infinity; AUC_{last}, area under plasma concentration-time profile from time 0 to time of last quantifiable concentration; C_{max}, maximum observed plasma concentration; CV, coefficient of variation; FDC, fixed-dose combination; N, number of subjects in the treatment group and contributing to the summary statistics; n, number of subjects with reportable t_{1/2} and AUC_{inf}; PK, pharmacokinetics; SD, standard deviation; t_{1/2}, terminal half-life; T_{max}, time to maximum plasma concentration.

**Subjects**

Healthy subjects (female and male) aged between 18 and 55 years with a body mass index of 18.5-30 kg/m² and total body weight > 50 kg were eligible for inclusion. “Healthy” was defined as lack of any clinically relevant abnormalities identified through a detailed medical history/full physical examination, which included monitoring blood pressure and pulse rate, 12-lead electrocardiogram, and clinical laboratory tests. The main exclusion criteria included a positive urine test for drugs of abuse or illicit drug substances; any history within 6 months of screening for alcohol abuse or binge drinking and/or any other illicit drug use or dependence; any clinical signs of a significant malabsorption condition; an estimated glomerular filtration rate < 80 mL/min/1.73 m², based on the 4-variable Modification of Diet in Renal Disease equation; known hypersensitivity or intolerance to any SGLT2 inhibitor or metformin; and pregnant or breastfeeding women.

**Pharmacokinetic Assessments**

Serial blood samples for PK analysis of metformin were obtained from each subject predose (0 hours) and up to 72 hours postdose in each period. Under fed conditions, predose PK samples were collected prior to consumption of the high-fat breakfast. Plasma samples were analyzed for metformin concentrations at WuXi AppTec (Shanghai, China) using a validated, sensitive, and specific high-performance liquid chromatography-tandem mass spectrometry method.
Table 3. Statistical Summary of Treatment Comparisons Between the Metformin Component of the Ertugliflozin/Metformin FDC Versus Individual Components Administered Under Fasted or Fed Conditions

| Treatment Comparison | Condition | AUC<sub>last</sub> | C<sub>max</sub> |
|----------------------|-----------|--------------------|---------------|
| Ertugliflozin/metformin 2.5/500 mg FDC versus coadministered | Fasted | 106.80 (96.17-118.61) | 108.27 (95.69-122.50) |
| Ertugliflozin/metformin 2.5/500 mg FDC versus coadministered | Fed | 98.65 (92.79-104.87) | 101.46 (97.54-105.52) |
| Ertugliflozin/metformin 7.5/850 mg FDC versus coadministered | Fasted | 98.87 (91.88-106.40) | 101.13 (90.58-112.92) |
| Ertugliflozin/metformin 7.5/850 mg FDC versus coadministered | Fed | 105.80 (95.99-116.62) | 98.67 (91.50-106.40) |

AUC<sub>last</sub>, area under plasma concentration-time profile from time 0 to time of last quantifiable concentration; C<sub>max</sub>, maximum observed plasma concentration; CI, confidence interval; C<sub>max</sub>, maximum observed plasma concentration; FDC, fixed-dose combination; GMR, geometric mean ratio.

Safety Assessments

Safety assessments were conducted at screening and throughout the duration of the study. These assessments included adverse events (AEs), blood pressure, pulse rate, physical examination, and clinical laboratory parameters. Subjects were followed up with a phone call 14 ± 3 days after the last dose of study treatment in period 2 was administered to assess for AEs. AEs were classified using the Medical Dictionary for Regulatory Activities (version 19.0) dictionary.

Statistical Analysis

PK parameters were assessed for each subject under fasted or fed conditions using noncompartmental analysis of plasma concentration-time data. These included area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUC<sub>inf</sub>), AUC from time 0 to last quantifiable concentration (AUC<sub>last</sub>, primary end point), maximum observed plasma concentration (C<sub>max</sub>, primary end point), time for C<sub>max</sub> (T<sub>max</sub>), and terminal half-life (t<sub>1/2</sub>). Samples below the LLOQ were set to 0 in the calculation of summary statistics and for PK analysis. Natural log-transformed AUC<sub>last</sub> and C<sub>max</sub> values for metformin were calculated for fasted and fed cohorts using a mixed-effects model that included sequence, period, and treatment as fixed effects and subject within sequence as a random effect. Estimates for the adjusted (least-squares) mean differences and 90% confidence intervals (CIs) and estimates of the ratio of adjusted geometric means (test:reference [FDC:coadministered]) and 90%CI for the ratio were obtained using previously described methods. For each FDC strength, the FDC tablet will be considered bioequivalent to coadministration if the 90%CIs for the geometric mean ratios (GMRs) for metformin AUC<sub>last</sub> and C<sub>max</sub> fell within 80% and 125%. PK parameters were calculated using electronic noncompartmental analysis (eNCA, version 2.2.4), a Pfizer internally validated software.

A sample size of 16 subjects per study was estimated to provide 91.5% power that the 90%CI for the ratio of the GMR would lie within the acceptance criteria for each of the metformin PK parameters (AUC<sub>last</sub> and C<sub>max</sub>) in the fasted state. A sample size of 12 subjects per study was estimated to provide 95.7% power that the 90%CI for the ratio of the GMR would lie within the acceptance region for each of the metformin PK parameters (AUC<sub>last</sub> and C<sub>max</sub>) in the fed state. The sample size calculations assumed a true GMR of 1.05 and were based on estimates of within-subject standard deviations (SDs) of 0.1563 and 0.1190 for metformin AUC<sub>last</sub> in the fasted and fed states, respectively. These estimates were obtained from past crossover studies conducted by Pfizer Inc and/or Merck & Co., Inc., Kenilworth, New Jersey.

Results

Study Subjects

A total of 32 subjects (18 in the fasted condition and 14 in the fed condition) were enrolled in each study; all participants completed the study and were included in both the PK and safety analyses. The demographic
Figure 3. Individual values and geometric and arithmetic means of plasma metformin AUC_{last} and C_{max} following a single oral dose of ertugliflozin coadministered with Canadian-sourced metformin (Glucophage) or as a fixed-dose combination (FDC) under fasted or fed conditions. Open circles identify individual subject data, and closed circles identify geometric means. Offset closed triangles identify arithmetic mean (with standard deviation). Box plots provide medians and 25% and 75% quartiles, with whiskers extended to the minimum/maximum values. AUC_{last}, AUC from time 0 to last quantifiable concentration; C_{max}, maximum observed plasma concentration.
and baseline characteristics of the study populations are shown in Table 1. In each study, the majority of subjects were black (59%-69%). In general, the baseline demographics and characteristics were well balanced between the fasted and fed cohorts within each study.

**Pharmacokinetic Assessments**

Mean plasma concentration-time profiles for metformin were nearly superimposable following administration of the FDC formulations and coadministration of the respective individual components under fasted or fed conditions (Figure 2). A descriptive summary of plasma metformin PK parameter values is provided in Table 2. The arithmetic and geometric means for metformin AUC<sub>inf</sub>, AUC<sub>last</sub>, and C<sub>max</sub> were similar between the FDC and the corresponding coadministered tablets for each of the dose combinations studied under either fasted or fed conditions. For each treatment (FDC and coadministered tablets), metformin median T<sub>max</sub> was 2 hours under fasted conditions and ranged from 2.5 to 4 hours under fed conditions. Similarly, metformin mean t<sub>1/2</sub> ranged from 8.7 to 16.7 hours under fasted conditions and from 13.1 to 22 hours under fed conditions across the 2 studies.

Treatment comparisons for the ertugliflozin/metformin FDCs and coadministration of individual components are summarized in Table 3. The GMRs (90%CIs) (test:reference [FDC:coadministered]) of metformin AUC<sub>last</sub> and C<sub>max</sub> for both dose strengths under fasted or fed conditions fell within the bioequivalence acceptance criteria (80%-125%), indicating lack of any meaningful differences in the metformin component of the ertugliflozin/metformin FDC tablets with metformin (500 or 850 mg) coadministered with ertugliflozin (2.5 or 7.5 mg) in either study. Individual values and geometric means of metformin AUC<sub>last</sub> and C<sub>max</sub> for both dose strengths under fasted or fed conditions are shown in Figure 3.

**Safety**

There were no reports of deaths, serious AEs, severe AEs, temporary or permanent discontinuations, or dose reductions because of AEs following administration of a single oral dose of ertugliflozin and metformin as an FDC or when coadministered as individual components. Incidence of treatment-emergent AEs was similar when treatment was administered as the FDC tablet and when coadministered as individual components. Gastrointestinal (GI) events and headache were the most commonly reported AEs. A total of 7 subjects assigned to an FDC reported GI events (1 in ertugliflozin/metformin 2.5/500 mg fed, 2 in ertugliflozin/metformin 2.5/500 mg fasted, 3 in ertugliflozin/metformin 7.5/850 mg fed, 1 in ertugliflozin/metformin 7.5/850 mg fasted), and 14 subjects with concomitant administration (1 in ertugliflozin/metformin 2.5/500 mg fed, 3 in ertugliflozin/metformin 2.5/500 mg fasted, 7 in ertugliflozin/metformin 7.5/850 mg fed, 3 in ertugliflozin/metformin 7.5/850 mg fasted). Headache was reported by a total of 4 subjects assigned to FDC (2 in ertugliflozin/metformin 2.5/500 mg fed, 2 in ertugliflozin/metformin 7.5/850 mg fed) and 2 subjects with concomitant administration (2 in ertugliflozin/metformin 2.5/500 mg fed). Most reported AEs were of mild intensity, except for 6 events of moderate intensity. Five of these moderate AEs were reported by subjects assigned to an FDC: headache (1 in ertugliflozin/metformin 2.5/500 mg fasted, 2 in ertugliflozin/metformin 7.5/850 mg fed), constipation (1 in ertugliflozin/metformin 7.5/850 mg fed), and nausea (1 in ertugliflozin/metformin 2.5/500 mg fasted). There were no clinically significant laboratory abnormalities or changes in blood pressure or pulse rate.

**Discussion**

The main purpose of the 2 studies reported here was to demonstrate the bioequivalence of the metformin component in ertugliflozin/metformin FDC tablets (2.5/500 or 7.5/850 mg) to metformin 500 or 850 mg coadministered with 2.5 or 7.5 mg ertugliflozin, respectively, under fasted and fed conditions to support the registration of the FDC tablets in Canada.

Bioequivalence of both the 500- and 850-mg doses of metformin in the FDC to the respective doses of metformin was demonstrated under both fasted and fed conditions, as the 90%CIs of the GMRs of AUC<sub>last</sub> and C<sub>max</sub> for metformin fell within the acceptable range of 80%-125%. In addition, multimedia dissolution tests showed that both FDC tablets (2.5/500 or 7.5/850 mg) dissolved rapidly, showing > 85% release in 15 minutes. Therefore, both strengths of the ertugliflozin/metformin FDC tablets (2.5/500 and 7.5/850 mg) can be considered bioequivalent to the respective strengths of ertugliflozin and metformin when coadministered.

Metformin exhibits nonlinear PK following single-dose administration because of saturable absorption, resulting in a less than proportional increase in exposure with increasing dose. Therefore, a single-dose study using the lower 2 doses of metformin (500 and 850 mg) under fasted or fed conditions was chosen for these studies as per Health Canada Guidance to demonstrate the bioequivalence of the metformin component in the FDC tablets to the respective strengths of metformin. A phase 1 study on the effect of food on the ertugliflozin/metformin FDC (7.5/1000 mg)
indicated that food had no clinically relevant impact on the PK of the FDC or the individual components.\textsuperscript{15}

Bioequivalence of ertugliflozin and metformin at various strengths of the ertugliflozin/metformin tablet and coadministration of individual components (ertugliflozin coadministered with either US-sourced or EU-sourced Glucophage) was demonstrated in 4 pivotal BE studies.\textsuperscript{28} As the reference and test treatments for ertugliflozin in the studies presented here are the same as were used in 4 pivotal studies conducted earlier (in which bioequivalence was demonstrated), blood samples for assessing ertugliflozin were not collected, and bioequivalence of the ertugliflozin component was not evaluated.

The standard dose regimen for ertugliflozin is once-daily dosing; however, as the ertugliflozin/metformin FDC tablet contains an immediate-release formulation of metformin, which is usually dosed twice daily, the recommended dosing of the FDC tablet is also twice daily. A phase 1 PK/PD study evaluating ertugliflozin exposure as assessed by AUC over 24 hours (AUC\textsubscript{24}) and urine glucose excretion over 24 hours (UGE\textsubscript{24}) at steady state demonstrated equivalence of AUC\textsubscript{24} and similarity of UGE\textsubscript{24} at the same total daily dose of ertugliflozin, regardless of whether ertugliflozin was dosed once daily or twice daily (2.5 mg twice daily vs 5 mg once daily and 7.5 mg twice daily vs 15 mg once daily).\textsuperscript{31} These data support administration of ertugliflozin in divided doses twice daily as a component of the ertugliflozin/metformin FDC.

The bioequivalence results from the 2 current phase 1 studies, together with the demonstrated glycemic efficacy of coadministration of ertugliflozin and metformin in the VERTIS MET study,\textsuperscript{7} suggest that the FDC formulation of ertugliflozin and metformin will provide an incremental benefit in T2DM patients who are not adequately controlled on metformin monotherapy. The ertugliflozin/metformin FDC formulation might be preferred by many patients owing to the convenience of combination treatment without the need to coadminister 2 separate tablets. In addition, the FDC tablets were generally well tolerated in the 2 studies reported here. The observed gastrointestinal-related AEs may have been because of metformin, as these are some of the commonly observed AEs reported with the use of metformin.\textsuperscript{32}

**Conclusion**

In summary, the studied doses of the metformin component of the ertugliflozin/metformin FDC tablets (ertugliflozin 2.5/metformin 500 mg and ertugliflozin 7.5/metformin 850 mg) are bioequivalent to the respective doses of metformin when coadministered with ertugliflozin under fasted or fed conditions. Ertugliflozin plus metformin either coadministered as the FDC tablet or as individual tablets under fasted or fed conditions was safe and well tolerated in healthy subjects. These results support bridging of PK, pharmacodynamics, safety, and efficacy data gathered through the phase 3 VERTIS MET\textsuperscript{7} study, which include ertugliflozin/metformin FDC tablets of various strengths.

**Acknowledgments**

Editorial support was provided by Anil Sindhurakar, PhD, of Engage Scientific Solutions (Fairfield, Connecticut) and was funded by Pfizer Inc., New York, New York, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.

**Conflicts of Interest**

Vikas Kumar Dawra, Kathleen Pelletier, Kyle Matschke, Haihong Shi, Anne Hickman, and Vaishali Sahasrabudhe are employees of Pfizer Inc., New York, New York, and may own shares/stock options in Pfizer Inc. Susan Zhou is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and may own stock in Merck & Co., Inc., Kenilworth, New Jersey. Rajesh Krishna was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, at the time the studies were conducted.

**Funding**

These studies were sponsored by Pfizer Inc., New York, New York, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.

**Data-Sharing Statement**

On request and subject to certain criteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual deidentified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the United States and/or European Union or (2) in programs that have been terminated (ie, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions and for which an exception does not apply via a secure portal. To gain access, data requesters must enter into a data access agreement with Pfizer.
References

1. Kalougkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39(9):1609-1619.

2. Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011;54(8):2952-2960.

3. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502.

4. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54(7):691-708.

5. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721-728.

6. Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20(6):1453-1460.

7. Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520-529.

8. Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530-540.

9. Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9(1):253-268.

10. Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111-1120.

11. Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2018;9(1):193-207.

12. Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49-66.

13. Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019;21(4):1027-1036.

14. Ji L, Liu Y, Miao H, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474-1482.

15. Sahasrabudhe V, Fediuk DJ, Matschke K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed-dose combinations ertugliflozin/sitagliptin and ertugliflozin/metformin. Clin Pharmacol Drug Dev. 2019;8(5):619-627.

16. Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432-1443.

17. US Food and Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry. [FDA Guidance]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070246.pdf. Published 2000. Accessed October 19, 2000.

18. Raje S, Callegari E, Sahasrabudhe V, et al. Novel application of the two-period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin. Clin Transl Sci. 2018;11(4):405-411.

19. Dawra VK, Cutler DL, Zhou S, et al. Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(3):314-325.

20. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent erugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445-456.

21. Sahasrabudhe V, Terra SG, Hickman A, et al. Pharmacokinetics of single-dose ertugliflozin in patients with hepatic impairment. Clin Ther. 2018;40(10):1701-1710.

22. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98-S110.
23. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia*. 2017;60(9):1577-1585.

24. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics*. 2012;22(11):820-827.

25. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *Br J Clin Pharmacol*. 1981;12(2):235-246.

26. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. *Drugs*. 2003;63(18):1879-1894.

27. Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. Metformin-clinical pharmacology in PCOs. *JM edL i f e*. 2015;8(2):187-192.

28. Dawra VK, Liang Y, Shi H, et al. Bioequivalence of ertugliflozin/metformin fixed-dose combination tablets and coadministration of respective strengths of individual components. *Clin Pharmacol Drug Dev*. 2020;9(1):50-61.

29. Health Canada. Guidance Document. Comparative Bioavailability Standards: Formulations Used for Systemic Effects. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/prodpharma/appli-demande/guide-ld/bio/comparative-bioavailability-standards-formulations-used-systemic-effects.pdf. Published 2018. Accessed October 19, 2020.

30. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med*. 2006;145(4):247-254.

31. Dawra VK, Liang Y, Shi H, et al. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects. *Int J Clin Pharmacol Ther*. 2019;57(4):207-216.

32. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. *Am J Med*. 1997;103(6):491-497.

**Supplemental Information**

Additional supplemental information can be found by clicking the Supplements link in the PDF toolbar or the Supplemental Information section at the end of web-based version of this article.